https://doi.org/10.55788/efeed97c
Many patients with advanced, non-curable lung cancer report physical and mental (and sometimes financial) issues that lead to poor quality-of-life. Therefore, guidelines recommend the early integration of palliative and oncology care, given robust evidence that this care model improves quality-of-life and other important outcomes. However, most patients do not receive early palliative care in the outpatient setting, due to limited access and resources. Telehealth can overcome these barriers.
The randomised REACH PC trial (NCT03375489) evaluated the equivalence of the effect of early palliative care delivered via video versus in-person visits on patient-reported quality-of-life in adult patients with advanced NSCLC and their caregivers.
The participants (n=1,250) were 1:1 randomised to receive palliative care via monthly in-person visits or monthly video visits (after an initial in-person visit). The patient characteristics were comparable between groups. The primary outcome measurement was quality-of-life determined by FACT-L at 12, 24, 36, and 48 weeks of follow-up. Dr Joseph Greer (Harvard Medical School, MA, USA) presented interim results at 24 weeks of follow-up [1].
Of the participants in the video visit group, 66% completed 24-week FACT-L, versus 69% in the in-person visit group. Topics addressed during the visits did not differ between the groups. Quality-of-life after 24 weeks was equivalent in both groups (mean score 99.67 vs 97.67; within the equivalence margin of 4 points). Satisfaction with care, and anxiety and depression scores did also not differ between the groups at 24 weeks of follow-up. The attendance of caregivers at the visits was significantly higher in the in-person visit group (49.7% vs 36.6%; P<0.0001), likely due to required assistance with transportation.
Based on these results, Dr Greer concluded that “the effect of early palliative care on quality-of-life is equivalent whether the care is delivered in-person or by video. These findings underscore the potential to increase access to evidence-based early palliative care through telehealth delivery.”
- Greer JA, et al. Comparative effectiveness trial of early palliative care delivered via telehealth versus in-person amongst patients with advanced lung cancer: the REACH PC trial. Abstract LBA3, ASCO Annual Meeting 2024, 31 May–4 June, Chicago, IL, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Consolidation with durvalumab improves survival in LS-SCLC Next Article
First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC »
« Consolidation with durvalumab improves survival in LS-SCLC Next Article
First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC »
Table of Contents: ASCO 2024
Featured articles
Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06
Gastrointestinal: Colorectal Cancer
No survival benefit of tumour debulking for patients with multi-organ metastatic CRC
Thermal ablation of small-size colorectal liver metastases is non-inferior to resection
Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC
CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC
Gastrointestinal: Upper GI Cancer
FLOT outperforms CROSS in resectable oesophageal cancer
Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC
No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer
Breast Cancer
Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor
ctDNA is prognostic of worse outcomes for CDK4/6 therapy
Adjuvant avelumab significantly improves survival in early TNBC
High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy
Lung Cancer
Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC
First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC
Comparable benefit of video- and in-person-delivered palliative care
Consolidation with durvalumab improves survival in LS-SCLC
Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab
Melanoma
Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma
Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma
Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma
Genitourinary Cancer
Immune-enhancing nutrition does not affect complication rate of radical cystectomy
ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma
Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma
Genitourinary: Prostate Cancer
Metformin does not prevent progression of low-risk prostate cancer
Baseline ctDNA has both prognostic and predictive value in mCRPC
Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT
Gynaecological Cancer
Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer
No lymphadenectomy for advanced ovarian cancer without suspicious nodes
SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer
Novel regimen for HR-positive endometrial cancer on the way?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com